
Is there a new global health threat? Fungal superbugs spread panic with climate change expanding its reach
Another dangerous fungus causes lung issues
WHO lists 19 fungal species as urgent priorities
Live Events
Climate change could exacerbate the spread
Urgent need for antifungal innovation
FAQs:
(You can now subscribe to our
(You can now subscribe to our Economic Times WhatsApp channel
A new global health threat is emerging—drug-resistant fungal infections . These microscopic fungal spores like Coccidioides , responsible for valley fever , are infecting people who inhale them from air or soil, even in their own backyards.Torrence Irvin from California became critically ill after he unknowingly inhaled the spores. Doctors took nearly a year to correctly diagnose him. However, by that time, he had lost a significant amount of weight and nearly died.As per a CNN report, another survivor Rob Purdie contracted fungal meningitis after he inhaled spores while gardening and now depends on lifelong toxic treatments. Aspergillus fumigatus , another dangerous fungus, could spread across Europe, Asia, and the Americas, and will affect millions of vulnerable individuals. This fungus, a study said, thrives in warm, damp environments and could potentially infect people by invading their lungs, particularly those who have underlying health issues like asthma, cystic fibrosis, or weakened immune systems.The World Health Organisation (WHO) reportedly has enlisted nearly 6.5 million invasive fungal infections. This, they said, results in 3.8 million deaths globally each year and the numbers are climbing due to increasing drug resistance.They listed 19 fungal species under urgent priorities for new drug development, among which Aspergillus fumigatus is one. Other dangerous species include Cryptococcus neoformans (deadly meningitis), Candida auris (highly drug-resistant hospital infections) and Candida albicans (common yeast that can become invasive).The CNN report stated that developing antifungal drugs is especially challenging since fungi are genetically closer to humans than bacteria. This means, the treatments can harm human cells, which could result in kidney failure, liver damage, or other severe side effects.Dr Neil Clancy, an infectious disease specialist and associate professor of medicine at University of Pittsburgh, told CNN that if an antifungal drug is being made, it is crucial to come up with formulations that will not harm genes and human proteins.Experts have noted that changing climate patterns, wildfires, and dust storms likely expand the fungi's geographic reach. Reportedly, cases of Coccidioides infection have been reported in over 20 US states, including regions which previously were unaffected.The study on Aspergillus fumigatus stated it could expand across an additional 77 per cent of global territory by 2100 as climate change is accelerated. Researchers have estimated that 9 million people in Europe alone could be exposed to infection risks if fungus takes hold.Reportedly, the fungus can grow rapidly in compost at high temperatures and can survive the human body's internal heat of 37°C. It was also found thriving in extreme environments like Chernobyl's nuclear reactors.Experimental drugs like Olorofim offer hope, however, experts have warned that limited specialist access and lack of public awareness could leave many patients untreated or misdiagnosed. More research, better treatments, and physician training are urgently needed to confront this growing fungal superbug threat, stated the CNN report.Professor Elaine Bignell, co-director at the MRC Centre for Medical Mycology at Exeter University, said that the development of new antifungal treatments has been slow. One key reason, as per an NDTV report, is financial unattractiveness of investing in antifungal medicines.Reportedly, the antifungal medicines are costly to develop and often spotted as less profitable compared to others in drug market.They are fungal infections that no longer react to usual antifungal treatment, so they are more difficult to treat and are possibly fatal.WHO includes species such as Aspergillus fumigatus, Candida auris, Cryptococcus neoformans, and Coccidioides among the most lethal ones.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
3 hours ago
- Time of India
What is RSV and why are infants especially at risk in India?
Respiratory Syncytial Virus, commonly known as RSV, is the leading cause of respiratory illness in children and infants worldwide. In India, RSV has also become a major issue for parents as well as pediatricians, particularly in the post-monsoon and winter seasons when cases surge. Although the nation continues to establish complete surveillance information, existing studies in tertiary care facilities show that RSV contributes 30% to 50% of bronchiolitis and pneumonia incidents in children aged two years and below. RSV is usually responsible for the symptoms of a cold in older children and adults. Nevertheless, in infants—especially those under six months of age, those who were premature at birth, or those with underlying health issues—the virus may cause severe lower respiratory tract infections, including bronchiolitis (inflammation of small airways) and pneumonia. These two diseases usually require hospitalization, and hospitalization rates between 3 and 5 per 100 infants less than one year of age per year have been estimated in India. The risks are not equal throughout the nation. Geographic and socioeconomic variations account for both the risk of and outcome of RSV infection. Children living in lower-income populations or in densely populated urban environments can have increased exposure from lesser access to healthcare, suboptimal ventilation, and slower diagnosis. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Eat 1 Teaspoon Every Night, See What Happens A Week Later [Video] getfittoday Undo Seeing the international burden of RSV, the World Health Organization (WHO) recently supported maternal RSV vaccination as a prevention approach. This entails immunizing pregnant women so that antibodies are passed on to the unborn child, providing immunity in the vulnerable early months of life. Although not yet included in India's Universal Immunization Programme (UIP), Indian health authorities, such as the Indian Academy of Pediatrics, are in the process of evaluating the vaccine's safety, effectiveness, and affordability in India. Phased introduction in high-risk groups could be the initial step. Apart from vaccines, monoclonal antibodies too have been promising in the prevention of RSV-related complications. These provide passive immunity in a single dose of injection. But the big constraint is cost. Without government incentives or being covered under public health schemes, these therapies could prove to be out of reach for the majority of Indian families. Differential pricing models and collaborations with insurance companies will become paramount in order to expand access. More encouragingly, Indian drug makers are not idle either. Bharat Biotech and Serum Institute of India have initiated RSV research programs and are likely to bank on their experience in the production of pediatric and maternal vaccines. Tie-ups with global firms can also open the way for local production of monoclonal antibodies, leading to costs savings as well as wider availability. Experts put wide availability of RSV vaccines and antibodies in India at least 2 to 4 years down the road. Early access could start in corporate or private hospitals dealing with high-risk pregnancies. In the private sector, however, the incorporation of RSV prevention in the national immunization program will be crucial to making RSV vaccines and antibodies accessible and beneficial for all Indian infants—irrespective of birthplace. Article courtesy: Dr. Shreya Dubey - Consultant - Neonatology & Paediatrics, CK Birla Hospital, Gurugram Russia's Lavrov Sounds Alarm Over German Army Buildup Plan; 'Very Worrying, Need To…' One step to a healthier you—join Times Health+ Yoga and feel the change
&w=3840&q=100)

Business Standard
3 hours ago
- Business Standard
India recorded 8.6 mn deaths in 2022, down 15% from Covid peak: CRS data
India saw over 8.6 million registered deaths in 2022, marking a drop of more than 15 per cent compared to the 10.2 million deaths recorded in 2021, according to data from the Civil Registration System (CRS). This decline of 1.5 million deaths brought the country's mortality figures back in line with levels seen before the Covid-19 pandemic. The CRS report, released by the Office of the Registrar General of India and accessed by the Press Trust of India, highlighted the abnormal rise in deaths during 2021, when the second wave of the pandemic took a severe toll. In contrast, deaths in 2020 were 8.1 million, in 2019 they stood at 7.6 million, and in 2018, 6.9 million. 'In the case of registered deaths, the number has decreased from 10.2 million in 2021 to 8.6 million in 2022, i.e. a decrease of 15.4 per cent. Some of the major states, namely, Gujarat, Maharashtra, Madhya Pradesh, Andhra Pradesh, Tamil Nadu, Uttar Pradesh, Karnataka, West Bengal, Bihar and Haryana have contributed significantly to the decreased number of registered deaths,' the report stated. Government challenges WHO's Covid estimates As of July 26, 2022, the Indian government reported 526,000 deaths due to Covid-19. However, the World Health Organisation had estimated over 4.7 million Covid-linked deaths in India, a claim that was firmly rejected by the Indian government. 'India had registered a strong objection to the process, methodology and outcome of this unscientific modelling approach especially when India had provided authentic data published through the Civil Registration System by Registrar General of India to WHO,' the government stated in a response in the Lok Sabha on July 29, 2022. Rise in registered births in 2022 The CRS report also revealed that over 25.4 million births were registered in 2022 — an increase from 24.2 million in 2021, reflecting a growth of about 5.1 per cent. 'The number of registered births has increased from 24.2 million in 2021 to 25.4 million in 2022,' the report said. Nearly all states and Union Territories saw an increase in birth registrations, except for Bihar, Haryana, Himachal Pradesh, Sikkim, West Bengal, Ladakh, and Lakshadweep. 'Nine major states, namely Uttar Pradesh, Madhya Pradesh, Maharashtra, Jharkhand, Karnataka, Gujarat, Telangana, Chhattisgarh and Assam have contributed significantly to the increase in registered births in 2022 over 2021,' the report added. 'On the other hand, a decrease in registered births in six figures has been observed in two major states, namely West Bengal and Bihar during 2021-2022,' it said.


Hindustan Times
4 hours ago
- Hindustan Times
Health Talk: WHO flags RSV deaths in children, calls for new immunisation tools
The World Health Organisation (WHO) recently issued recommendations, including the effective use of immunisation products, to protect infants against Respiratory Syncytial Virus (RSV), which causes acute lower respiratory infections in children and can become life-threatening. RSV, one of the leading causes of under-five mortality globally (which refers to the death of children before their fifth birthday, typically expressed as a rate per 1,000 live births), is responsible for around 1 lakh deaths and over 3.6 million hospitalisations in children under the age of five every year, according to the United Nation health body. About half of these deaths occur in infants younger than six months of age. The vast majority (97%) of RSV deaths in infants occur in low- and middle-income countries, where there is limited access to supportive medical care such as oxygen or hydration. India also has a high disease burden, particularly around the rainy season. A 'position paper' published by WHO outlines recommendations for two immunisation products — a maternal vaccine that can be given to pregnant women in their third trimester to protect their infant, and a long-acting monoclonal antibody that can be administered to infants from birth, just before or during the RSV season. 'RSV is an incredibly infectious virus that infects people of all ages, but is especially harmful to infants, particularly those born premature, when they are most vulnerable to severe disease,' director of immunization, vaccines, and biologicals at WHO Kate O'Brien said in a statement. 'The WHO-recommended RSV immunisation products can transform the fight against severe RSV disease, dramatically reduce hospitalizations, and deaths, ultimately saving many infant lives globally,' he added. A 2021 study — Disease Burden Due to Respiratory Syncytial Virus in Indian Pediatric Population: A Literature Review — said, 'In India, epidemiology of RSV infection is well documented in young children (0-5 years) as compared to children from other age groups. The rates of RSV detection in various studies conducted in younger children (0-5 years) vary from 2.1% to 62.4% in India which is higher as compared to children from other age groups.' RSV usually causes mild symptoms similar to the common cold, including runny nose, cough, and fever. However, it can lead to serious complications — including pneumonia and bronchiolitis — in infants, young children, older adults, and those with compromised immune systems or underlying health conditions. Better management and putting in place preventive measures is largely the key to stopping any disease from turning big. The WHO recommendations will hopefully serve the purpose, and the world will see fewer deaths in children due to RSV.